Loading patent…
AssigneeAventis Behring GmbH
InventorsChin C. Huang, Takashi Enkoji, Laura Ho, Richard R. Kleszynski, Richard L. Weeks, Fred Feldman
Estimating the term…
A novel method of protecting blood coagulation factor IX from proteases during purification or storage is disclosed. High concentrations of one or more water soluble organic or inorganic salts are used to stabilize factor IX, contained within blood plasma-derived solutions, or contained within solutions derived from other sources, against conversion to clinically unacceptable peptide structures such as factor IXa, and/or degraded factor IX peptides. The technique is useful in stabilizing intermediate purity factor IX preparations during purification, and in maintaining the integrity of purified factor IX during long term storage. Stable high specific activity factor IX preparations are also disclosed.
A method of treating Christmas disease in a patient which comprises administering to such patient an effective amount of a therapeutic composition comprising an aqueous solution of purified factor IX having a specific activity of greater than about 50 units factor IX activity/mg protein, wherein the composition is capable of being stored for a period of time of about 2 weeks at a storage temperature up to 15-30° C. and wherein at the end of said period of storage the composition has a factor IX specific activity of greater than about 50 units and is free of factor IXa, degraded forms of factor IX and/or active forms of other clotting factors in concentrations which would tend to cause detectable adverse clinical effects in a human when said composition is administered in a therapeutic dose.
A method of treating Christmas disease in a patient which comprises administering to such patient an effective amount of a therapeutic composition comprising an aqueous solution of purified factor IX which is made using a method for purifying and preserving factor IX derived from human blood plasma or other source by separating factor IX from contaminating proteins which are in solution therewith by a purification process comprising at least two sequential separation steps, the improvement which comprises stabilizing factor IX in solution against activation to factor IXa or against degradation to peptides of altered length and/or conformation by the steps of (a) adding one or more soluble organic or inorganic salts to the factor IX-containing solution to a concentration of from about 0.7 to about 3 M prior to or during a first separation step, which concentration is sufficient to prevent or substantially minimize activation of or degradation of factor IX, but which concentration is insufficient to cause precipitation of, irreversible alterations in, or denaturation of the factor IX molecule, and (b) maintaining the salt(s) in the solution at said concentration until at least through commencement of a subsequent separation step in which the factor IX is separated from those impurities which tend to activate factor IX to factor IXa and/or to degrade factor IX to peptides of altered length and/or conformation.
A method of treating Christmas disease in a patient which comprises administering to such patient an effective amount of a therapeutic composition comprising an aqueous solution of purified fact-or IX which is made using a method of stabilizing factor IX which is derived from recombinant technology using bacterial, yeast or other cells against activation to factor IXa or against degradation to peptides of altered length and/or conformation which method comprises adding one or more soluble organic or inorganic salts to a solution containing said factor IX to a total concentration of salt of from about 0.7 to about 3 M, which concentration is sufficient to prevent or substantially minimize catalytic action by proteases upon factor IX, but at a total concentration of said salt or salts insufficient to cause precipitation of, irreversible alterations in, or denaturation of the factor IX molecule.
A composition which comprises a lyophilized powder, solution, suspension, or frozen solution or suspension, of factor IX having a specific activity of factor IX above about 50 units/mg of protein and which includes, on a percent by weight of protein basis, no more than about 0.1% of factor IXa, or no more than about 10% in total of one or more factor IX degradation peptides having molecular weights from approximately 40 to approximately 65 kDa.
Dependencies are inferred from the claim text.